Sonoma Biotherapeutics
Jessica Stitt, MBA is a global biotech financial executive with over 20 years of experience in corporate transactions, healthcare finance and strategy. She most recently served as Chief Financial Officer at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on disease of the eye, acquired by Novartis. Prior to Gyroscope, Stitt served as Vice President of Finance and Operations for MyoKardia, Inc., a biopharmaceutical company developing targeted therapies for the treatment of serious cardiovascular diseases, acquired by Bristol Myers Squibb. She served as Vice President of Finance and Investor Relations for Theravance Biopharma, Inc., after the company’s spin-off from Theravance, Inc., now Innoviva, Inc. She previously held roles in finance at Nektar Therapeutics, Alkermes and Blue Cross Blue Shield of Massachusetts.
Stitt holds an MBA from Simmons School of Management and a B.A. from Saint Anselm College.
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.